GERD. Gastro-esophageal reflux disease without esophagitis
Conditions
Interventions
Intervention 1: Intervention group: Addition of buspirone buccal tablet 10 mg/d to omeprazol capsule 20 mg/ d for treatment of GERD for 1 month. Intervention 2: Control group: Addition of buspirone pl
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: GERD disease in patients with more than 15 years old
Exclusion criteria
Exclusion criteria: History of confirmed hypersensitivity reaction to buspirone or omeprazol or any parts of formulation of buccal buspirone eGFR less than 10 ml/min/1.73m2 Liver failure (child pugh C) Pregnancy & lactation Concurrent use of thalidomide/ dapoxetine/MAOI/ conivaptane , tolvaptane/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of clinical symptoms of GERD (chest pain / regurgitation / dyspepsia/heart burn). Timepoint: Before intervention and 30 days after initiation of daily use of buccal buspirone and capsule omeprazole. Method of measurement: Interview with patients based on FSSG questionnaire and quality of life questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Record of Adverse drug reactions. Timepoint: During intervention. Method of measurement: Interview with patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactzahra sargashteh
Shahid Beheshti University of Medical Sciences
Outcome results
None listed